Amgen To Present At The RBC Healthcare Conference And The UBS Global Healthcare Conference
THOUSAND OAKS, Calif., May 16, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the RBC Health Care Conference at 8:30 a.m. ET and at the UBS Global Healthcare Conference at 2 p.m. ET on Tuesday, May 21, 2019, in New York City. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at both conferences. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About Amgen
Amgen is committed to unlocking the p...
Source: Amgen News Release - May 16, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Showcases Oncology Pipeline At ASCO 2019
Data From Largest Oncology Pipeline in Company's History
First-in-Human Data Evaluating Investigational AMG 510, the First KRASG12C Inhibitor to Reach Clinical Stage, in Solid Tumors
Potential Versatility of BiTE® Immuno-oncology Platform Reinforced With Phase 1 Asset Updates
THOUSAND OAKS, Calif., May 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that data from its oncology pipeline will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019. Seven investigational assets will be featured across a range of hematologic malignancie...
Source: Amgen News Release - May 15, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present At The Bank of America Merrill Lynch 2019 Health Care Conference
THOUSAND OAKS, Calif., May 10, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2019 Health Care Conference at 10 a.m. PT on Wednesday, May 15, 2019. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering f...
Source: Amgen News Release - May 10, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Sets Official Guinness World Record ™ for Most Osteoporosis Screenings for an Osteoporosis Campaign in 24 Hours
Healthcare Campaign Executed Across 10 Countries to Raise Awareness of the Importance of Predicting and Preventing Osteoporosis and Bone Fracture, Particularly in Post-Menopausal WomenThousand Oaks, Calif. (May 6, 2019) – Amgen, together with local healthcare partners in 10 countries around the world, set on May 5, 2019, a Guinness World Record title for the most osteoporosis screenings for an osteoporosis campaign in 24 hours. To break the existing world record, Amgen set out to screen at least a total of 3,000 people in 10 countries around the world -- to help them unders...
Source: Amgen News Release - May 6, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig ® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting
After Long-Term Aimovig Treatment, Two-Thirds of Chronic Migraine Patients Converted to Episodic Migraine, Experiencing 11 Fewer Migraine Days per Month on Average
Separate Study Showed the Majority of Episodic Migraine Patients on Aimovig Reported at Least a 50 Percent Reduction in Monthly Migraine Days at One Year, With One in Five Being Completely Migraine-Free
Aimovig is the Most Prescribed Anti-CGRP Therapy - Approximately 200,000 Patients in the U.S. Have Been Prescribed Aimovig Since Launch[1]
THOUSAND OAKS, Calif., May 2, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present new lon...
Source: Amgen News Release - May 2, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And Syapse Enter Precision Medicine Collaboration In Oncology
Supports Providers With Advanced Insight Tools and Research Opportunities
Generates Insights From Real-World Evidence for Potential Use in Regulatory Filings
THOUSAND OAKS, Calif. and SAN FRANCISCO, May 2, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, today announced a precision medicine collaboration in oncology.
Under the terms of the agreement, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology. This effort will...
Source: Amgen News Release - May 2, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Ignites A Social Fitness Movement To Support The Fight Against Heart Disease And Cancer
Amgen Breakaway Challenge Turns Walking, Running or Cycling Miles Into Support for Eight Independent Nonprofit Advocacy Organizations
THOUSAND OAKS, Calif., May 1, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support the fight against heart disease and cancer. Amgen's Breakaway Challenge joins together Breakaway from Cancer® and Breakaway from Heart Disease™ and serves as a complementary component to its title sponsorship of the Amgen Tour of California, a world-class cyclin...
Source: Amgen News Release - May 1, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Reports First Quarter 2019 Financial Results
THOUSAND OAKS, Calif., April 30, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2019. Key results include:
Total revenues were unchanged at $5.6 billion in comparison to the first quarter of 2018.
Product sales declined 1 percent globally. New and recently launched products including Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib) showed double-digit growth.
GAAP earnings per share (EPS) decreased 2 percent to $3.18 driven by higher total operating expenses, offset partially by lower weighted-average shares outstanding.
...
Source: Amgen News Release - April 30, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces Webcast of 2019 First Quarter Financial Results
THOUSAND OAKS, Calif., April 25, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 30, 2019, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and th...
Source: Amgen News Release - April 25, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida
Long-Established Science Education Program to Give Local Secondary School Students Hands-On Biotechnology Lab Experience
TAMPA, Fla., April 17, 2019 /PRNewswire/ -- The Amgen Foundation, together with the University of South Florida (USF), today announced the launch of the Amgen Biotech Experience (ABE) program in Tampa, Florida, as part of its long-standing science education program. Globally, ABE is expected to reach nearly 900,000 secondary school students by 2020 in 20 regions around the world.
For nearly 30 years, ABE has empowered high school science teachers to implement real-world biotechnology labs in their...
Source: Amgen News Release - April 17, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
EVENITY ™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
New Therapy to Cost One-Third Less Than Other Bone-Building Agents Over Full Course of Therapy
THOUSAND OAKS, Calif., April 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was approved by the U.S. Food and Drug Administration (FDA) on April 9, 2019, for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
"Osteoporosis is a silent disease that can lead to devastating consequences. Unfortunately, only 20 percent of women who have experienced a fracture receive any type of oste...
Source: Amgen News Release - April 15, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
FDA Approves EVENITY ™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
One in Two Women in the United States Will Suffer a Fracture in Her Lifetime Due to Osteoporosis(1)
EVENITY is the First and Only Bone Builder With a Dual Effect That Both Increases Bone Formation and Decreases Bone Loss(2)
EVENITY Rapidly Reduces Fracture Risk and Builds New Bone With 12 Months of Therapy(2)
THOUSAND OAKS, Calif. and BRUSSELS, April 9, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fractu...
Source: Amgen News Release - April 9, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Presents New Data At WCO-IOF-ESCEO 2019 Revealing Osteoporosis Treatment Gap In Europe
Study Shows 55 Percent of Women Over 70 Years Old are at Risk of Fragility Fractures With 75 Percent of Them not Treated for Osteoporosis
THOUSAND OAKS, Calif., April 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data presented from a cross-sectional study revealing a gap in the diagnosis and treatment of osteoporosis in Europe. The real-world study of osteoporosis management in primary care revealed that 75 percent of female patients aged 70 years and older who were at increased risk of fragility fractures were not treated for osteoporosis. The treatment gap was much lower in those with a recorded ...
Source: Amgen News Release - April 7, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure to Continue Without Changes
THOUSAND OAKS, Calif., and SOUTH SAN FRANCISCO, Calif., and SURESNES, France, March 20, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the first planned interim analysis, which included consideration of pre-specified criteria for futility. The DMC reviewed data from GALACTIC-HF and recommended that this Phase 3 clinical trial of omecamti...
Source: Amgen News Release - March 20, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha ® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke
VESALIUS-CV is the Latest Study in Amgen's PROFICIO Clinical Program Investigating the Impact of Repatha on CVD in Multiple Patient Populations
Phase 3 Study Will Enroll High-Risk Patients who Have Significant Atherosclerotic Disease or Diabetes and are at High Risk for a First Cardiovascular Event
THOUSAND OAKS, Calif., March 15, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans to conduct VESALIUS-CV, a multinational clinical outcomes study for Repatha® (evolocumab) which will involve at least 13,000 patients worldwide at high risk of experiencing a first cardiovascular (CV) event, despite optimized ...
Source: Amgen News Release - March 15, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
